HCW Biologics Inc

HCWB

Company Profile

  • Business description

    HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

  • Contact

    2929 N. Commerce Parkway
    MiramarFL33025
    USA

    T: +1 954 842-2024

    https://www.hcwbiologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    35

Stocks News & Analysis

stocks

ASX energy share undervalued ahead of earnings

Pricing strength outweighs temporary production headwinds.
stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks

This onetime AI market darling is now surprisingly undervalued

This AI leader qualifies as a GARP stock today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.4069.700.77%
CAC 408,615.17105.531.24%
DAX 4026,006.92377.681.47%
Dow JONES (US)52,485.03276.970.53%
FTSE 10010,860.008.05-0.07%
HKSE26,009.40124.970.48%
NASDAQ25,373.85251.681.00%
Nikkei 22563,754.90607.12-0.94%
NZX 50 Index13,774.9375.650.55%
S&P 5007,489.7252.090.70%
S&P/ASX 2009,019.3070.300.79%
SSE Composite Index3,809.6622.60-0.59%

Market Movers